Virus neutralization is one of the primary mechanisms by which vaccines protect against infectious diseases. When a vaccine is administered, it triggers the immune system to produce antibodies that recognize and bind to viral particles. These neutralizing antibodies block the virus from attaching to and entering host cells, preventing infection. Neutralization is a key aspect of vaccine design, as vaccines aim to generate antibodies that target the virus's surface proteins or other essential components, rendering it harmless. For example, vaccines for diseases like COVID-19 and influenza stimulate the immune system to produce antibodies that can neutralize the respective viruses, offering protection against future infections. The strength and specificity of these antibodies are crucial for long-lasting immunity, as viruses that undergo mutations may evade immune recognition. Thus, vaccine developers must continuously monitor viral evolution to ensure that vaccines remain effective in neutralizing emerging strains.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States